about
Development, cytokine profile and function of human interleukin 17-producing helper T cellsT helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis.From interleukin-23 to T-helper 17 cells: human T-helper cell differentiation revisited.Development and function of TH17 cells in health and disease.Accelerating bleaching in vitiligo: balancing benefits versus risks.IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes.MicroRNA-211 Regulates Oxidative Phosphorylation and Energy Metabolism in Human Vitiligo.HSP70 potentiates interferon-alpha production by plasmacytoid dendritic cells: relevance for cutaneous lupus and vitiligo pathogenesis.Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.Meeting report: Vitiligo Global Issues Consensus Conference Workshop "Outcome measurement instruments" and Vitiligo International Symposium, Rome, Nov 30-Dec 3rd.Circulating and gut-resident human Th17 cells express CD161 and promote intestinal inflammation.Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2/EP4 receptor signaling.IL-17 in the rheumatologist's line of sight.Biomarkers of Therapeutic Response in the IL-23 Pathway in Inflammatory Bowel DiseasePre- vs. post-pubertal onset of vitiligo: multivariate analysis indicates atopic diathesis association in pre-pubertal onset vitiligo.Development and validation of the K-VSCOR for scoring Koebner's phenomenon in vitiligo/non-segmental vitiligo.Autoimmune memory T helper 17 cell function and expansion are dependent on interleukin-23.IL-27 blocks RORc expression to inhibit lineage commitment of Th17 cells.Vitiligo Skin Is Imprinted with Resident Memory CD8 T Cells Expressing CXCR3.Malvidin-3-O-β glucoside, major grape anthocyanin, inhibits human macrophage-derived inflammatory mediators and decreases clinical scores in arthritic rats.Comment: The mystery of melanocyte demise in vitiligo.Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo.Cell delivery using microneedle devices: a new approach to treat depigmenting disorders.A Score with a VESted Interest in Vitiligo.Elevated total serum IgE in vitiligo might be protective for other autoimmune diseasesA Th2 Cytokine Interleukin-31 Signature in a Case of Sporadic Lichen AmyloidosisExpression of interleukin-1 alpha in amicrobial pustulosis of the skin folds with complete response to anakinraType I interferon signature in the initiation of the immune response in vitiligoVitiligo as a skin memory disease: The need for early intervention with immunomodulating agents and a maintenance therapy to target resident memory T cellsDual efficacy of dupilumab in a patient with concomitant atopic dermatitis and alopecia areataVitiligo therapy: restoring immune privilege?Inflammasome Activation Characterizes Lesional Skin of Folliculitis DecalvansInflammatory skin eruptions induced by anti-tumour necrosis factor-α therapy differ undeniably from psoriasis or eczemaVitiligo-like lesions in patients receiving anti–programmed cell death-1 therapies are distinct from spontaneously occurring active vitiligoSkin Inflammation Induced by the Synergistic Action of IL-17A, IL-22, Oncostatin M, IL-1 , and TNF- Recapitulates Some Features of PsoriasisA role for T cell-derived interleukin 22 in psoriatic skin inflammationOncostatin M Secreted by Skin Infiltrating T Lymphocytes Is a Potent Keratinocyte Activator Involved in Skin InflammationPhenotype and function of circulating memory T cells in human vitiligoImbalance of peripheral follicular helper T lymphocyte subsets in active vitiligo
P50
Q29617131-5E22B0D5-49BC-4BC8-A219-5F75EECC2E1AQ34107156-CE84851A-8925-4AB9-92F6-52F9574D6B01Q37374943-9F50024B-C860-4AA7-A095-12324D59845FQ37467750-DBF82D9B-A08E-4B16-BEC2-09164CE467F7Q38231335-D5BBE673-6C48-46EE-9707-1806C0FEA7A7Q38329713-E37E0C5F-EFAE-4FB0-932D-0FB39821C1D2Q38703571-3D4EF7C3-D465-4266-BD20-D1835C732066Q38852458-E6FA0ED1-6734-4644-8461-A6A93418A4C3Q39419931-E87AB9E3-2686-4751-BB0E-5AA8E4A28146Q40256899-03BFCF3E-8A1D-48D2-8943-249600B6E3D9Q41330684-3B30F875-9168-4126-B6FE-29D04072D638Q41330743-700AEF56-4112-496B-9308-D8435B78CD5FQ41890076-C10F375F-8CF5-45A2-B59E-D178D6075FB6Q42177330-0E641414-8FBA-4DE0-B3FE-8775C316E13AQ43494518-10E69215-A2DE-4A5E-9A4F-39E3677E4F0BQ44036476-E71E7777-6C2B-46EC-8312-F0C29859226FQ44344487-814AC2E5-DC0F-49E3-8510-BC7B80EF8F79Q46043684-F32E87A9-7E49-4DCE-8C9A-64FC0FA140D9Q50014282-5654AA3E-84B6-4225-909A-3209150D6C2EQ50489324-ECBE5766-4311-4606-A7BF-F0A8497B62CCQ51062452-27621FF4-D3AC-419A-81B8-EB0371A84F62Q51187318-4BE816CF-B252-42E0-A4FC-333368DBDFE3Q52623236-37FD744C-2DF1-4E97-85DB-FBF237B01851Q52983437-6DA7B301-7506-4AD4-87FF-91ED3A5175FDQ56996152-FFBE1D3B-D5BA-4C8E-B3DB-D833A959D1A3Q56996462-41967120-557A-49AE-A205-860455250A4FQ56996515-D436CBB1-37D7-483B-AF30-AECA0828C2ADQ56996562-5C0D3C29-5824-4AD8-A9AD-1AE18E8C7E1EQ62660638-8E159F81-AE86-4B91-ADF6-61F5C0C0D341Q62660642-F599803F-1670-4ACE-B507-F8584DD501D7Q62660648-1DF996FC-D84E-4DB0-A5FB-B357085A9811Q62662113-1D732938-0590-43A5-AB52-D0A028CE3098Q62662115-4BE5C62A-6BBD-4EDB-A5A4-A2F4FD51E3ADQ62662117-9E7109FC-2B00-46BC-A561-293171AB57D4Q62662119-39316ADA-F05B-428E-8188-94599FA4E2DFQ62662121-220E3F58-A8B3-428C-8609-CEF36F856697Q62662122-6C62AB44-6A7D-4A1A-AD7E-0A8ECEC2A7DAQ89505877-A07E5ABC-8550-43A5-AD1E-2402DC4BA6D4Q90537737-287498A9-B8D8-4A45-89C4-90C8237C2D2A
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0003-4428-1222
@en
name
K. Boniface
@nl
Katia Boniface
@en
Katia Boniface
@es
type
label
K. Boniface
@nl
Katia Boniface
@en
Katia Boniface
@es
altLabel
K. Boniface
@en
prefLabel
K. Boniface
@nl
Katia Boniface
@en
Katia Boniface
@es
P106
P1153
8300423700
P21
P31
P496
0000-0003-4428-1222